Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs TransMedics Group Inc (TMDX) Price & Performance

Datadog IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs TransMedics Group Inc — how do they compare? Datadog Inc trades at $240.71 (market cap $88.61B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Datadog Inc is far larger — about 28.6× TransMedics Group Inc's market cap, and Datadog Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

DDOGTMDX
Market Cap
$88.61B$3.10B
Sector
TechnologyTechnology
52-Week High
$288.15$150.42
52-Week Low
$102.62$61.99
Enterprise Value
$84.90B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $241.00, down 7.58% amid a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. The stock shows elevated valuation ratios (P/E 493.56, P/S 22.83) but maintains robust revenue growth (36% YoY in Q2) and a high gross profit margin of 79.51%. Recent insider selling and mixed technical indicators contrast with an 83% analyst buy rating.

Outlook: Long-term growth driven by AI demand and net revenue retention above 120% supports upside to the $288.55 consensus target. Risks include valuation sensitivity, customer concentration, and execution pressure. The stock presents a growth opportunity with volatility near-term.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX